Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）
Sponsor: Beijing Tsinghua Chang Gung Hospital
Summary
Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51. Oteseconazole showed statistically significant and clinically meaningful treatment of severe VVC and was generally tolerated. The trial is a national multi-center, non-interventional observational real-world study, aiming to evaluate the effecacy and safety of oteseconazole in the treatment of patients with VVC. This study will include patients with severe vulvovaginal candidiasis (SVVC) . It is divided into prospective and retrospective parts.
Official title: Non-interventional Real-World Study of Oteseconazole in the Treatment of Vulvovaginal Candidiasis
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
3000
Start Date
2025-08-10
Completion Date
2030-08-10
Last Updated
2025-07-01
Healthy Volunteers
No
Conditions
Interventions
Oteseconazole (VT-1161) 150mg capsule
Subjects with SVVC will be treated by Oteseconazole with 600 mg (150 mg per capsule) on D1, 450 mg on D2